Talk:Deflazacort
Add topicLatest comment: 7 months ago by JF1006 in topic Update: Withdrawal of edit request
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Deflazacort.
|
some of the sections are only valid for the USA — Preceding unsigned comment added by 2.137.140.195 (talk) 11:14, 20 February 2018 (UTC)
"Delacort" listed at Redirects for discussion
[edit]
The redirect Delacort has been listed at redirects for discussion to determine whether its use and function meets the redirect guidelines. Readers of this page are welcome to comment on this redirect at Wikipedia:Redirects for discussion/Log/2025 November 12 § Delacort until a consensus is reached. —Myceteae🍄🟫 (talk) 18:11, 12 November 2025 (UTC)
Update: Withdrawal of edit request
[edit]I am withdrawing the edit request below. Please do not implement the proposed change at this time. Thank you. JF1006 (talk) 20:35, 19 December 2025 (UTC)
Edit request: Brand names (Deflazacort)
[edit] | The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE. |
 | This edit request by an editor with a conflict of interest has now been answered. |
COI disclosure: I am an employee of Tris Pharma and I am requesting that an uninvolved editor review and (if appropriate) implement the change below.
Current Wikipedia Page: Brand names
Deflazacort is sold in the United States under the brand name Emflaza after PTC Therapeutics, Inc. acquired all rights to Emflaza in March 2017.[15] Deflazacort is sold in the United Kingdom under the trade name Calcort;[8] in Brazil as Cortax, Decortil, Defcort and Deflanil; in India as Moaid, Zenflav, Defolet, DFZ, Decotaz, and DefZot; in Bangladesh as Xalcort; in Panama as Zamen; Spain as Zamene; and in Honduras as Flezacor.
Proposed Update: Brand names
Deflazacort is sold in the United States under the brand name Emflaza after PTC Therapeutics, Inc. acquired all rights to Emflaza in March 2017.[15] It is also available as an FDA-approved generic oral suspension marketed by Cranbury Pharmaceuticals, LLC. (a subsidiary of Tris Pharma), which received approval for its generic version of Emflaza oral suspension in April 2024 and is now commercially available in the U.S. market.<ref name="FDA-ANDA217813">{{cite web
|url=https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217813Orig1s000ltr.pdf
|title=ANDA approval letter: ANDA 217813 – Deflazacort Oral Suspension, 22.75 mg/mL
|website=Drugs@FDA
|publisher=U.S. Food and Drug Administration
|date=2024-04-25
|access-date=2025-12-18
}}</ref><ref name="TrisCranbury2024">{{cite web
|url=https://www.trispharma.com/cranbury-pharmaceuticals-receives-u-s-fda-approval-for-first-generic-version-of-emflaza-oral-suspension-deflazacort-for-duchenne-muscular-dystrophy/
|title=Cranbury Pharmaceuticals Receives U.S. FDA Approval for First Generic Version of Emflaza® Oral Suspension (deflazacort) for Duchenne Muscular Dystrophy
|website=Tris Pharma
|publisher=Tris Pharma, Inc.
|date=2024-06-12
|access-date=2025-12-18
}}</ref> Deflazacort is sold in the United Kingdom under the trade name Calcort;[8] in Brazil as Cortax, Decortil, Defcort and Deflanil; in India as Moaid, Zenflav, Defolet, DFZ, Decotaz, and DefZot; in Bangladesh as Xalcort; in Panama as Zamen; Spain as Zamene; and in Honduras as Flezacor.
— Preceding unsigned comment added by JF1006 (talk • contribs) 20:30, 18 December 2025 (UTC)